Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ESRD patients 18 years or older~* Stable on hemodialysis for more than 3 months~* Stable hemoglobin between 11-12 g/dl~* Stable arteriovenous (AV) fistula vascular access~* Stable anticoagulation and ESA regimen~* No active infection~* Able to sign informed consent and able to participate in the study~* Medically stable~Exclusion Criteria:~* Participation in another study which may interfere with the planned study~* Active infection~* Medical conditions which may interfere with the study (cardiac, liver disease, Hepatitis)~* Allergy to dialyzer membrane materials e.g. polysulfone~* Patients which cannot tolerate Heparin~* Female who are pregnant or planning to be pregnant~* Problem with or allergy to anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Solute Clearance (Type: ACTIVE_COMPARATOR): Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
- Hemocompatibility (Type: ACTIVE_COMPARATOR): Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
- Solute removal rate (Type: ACTIVE_COMPARATOR): Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .

Based on this trial design, predict the completion outcome and termination type (if applicable).